Brian M Nguyen1, Chelsea Halprin1, Yuliya Olimpiadi1, Peter Traum2, James J Yeh3, Christine Dauphine4. 1. Division of Surgical Oncology, Department of Surgery, Harbor-UCLA Medical Center, 1000 West Carson Box 25, Torrance, CA 90502, USA. 2. Department of Pathology, Harbor-UCLA Medical Center, 1000 West Carson Box 25, Torrance, CA 90502, USA. 3. Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, 1000 West Carson Box 25, Torrance, CA 90502, USA. 4. Division of Surgical Oncology, Department of Surgery, Harbor-UCLA Medical Center, 1000 West Carson Box 25, Torrance, CA 90502, USA. Electronic address: cdauphine@dhs.lacounty.gov.
Abstract
BACKGROUND: Excisional biopsy is currently recommended for the analysis of lymphadenopathy suspicious for lymphoma. This study aims to evaluate the efficacy and safety of image-guided core needle biopsy (IGCNB) for the diagnosis of lymphoma using a standard protocol for tissue acquisition and analysis. METHODS: All IGCNBs from 2008 to 2014 performed under the study protocol were included in analysis. Demographics, pathology results, additional studies, and follow-up information were recorded. RESULTS: Seventy-three IGCNBs were performed in 71 consecutive patients. Lymphoma was diagnosed in 37 patients (51%). All 37 patients (100%) were subtyped and treated based on IGCNB results. The remaining 36 IGCNBs in 34 patients did not have subsequent diagnosis of lymphoma in a mean follow-up of 15 months (range, 0 to 54 months). There were no complications. CONCLUSIONS: IGCNB performed under a standard protocol is effective and safe and should be considered as an initial diagnostic tool for the evaluation of lymphadenopathy suspicious for lymphoma.
BACKGROUND: Excisional biopsy is currently recommended for the analysis of lymphadenopathy suspicious for lymphoma. This study aims to evaluate the efficacy and safety of image-guided core needle biopsy (IGCNB) for the diagnosis of lymphoma using a standard protocol for tissue acquisition and analysis. METHODS: All IGCNBs from 2008 to 2014 performed under the study protocol were included in analysis. Demographics, pathology results, additional studies, and follow-up information were recorded. RESULTS: Seventy-three IGCNBs were performed in 71 consecutive patients. Lymphoma was diagnosed in 37 patients (51%). All 37 patients (100%) were subtyped and treated based on IGCNB results. The remaining 36 IGCNBs in 34 patients did not have subsequent diagnosis of lymphoma in a mean follow-up of 15 months (range, 0 to 54 months). There were no complications. CONCLUSIONS: IGCNB performed under a standard protocol is effective and safe and should be considered as an initial diagnostic tool for the evaluation of lymphadenopathy suspicious for lymphoma.
Authors: Alessandro Broccoli; Cristina Nanni; Alberta Cappelli; Francesco Bacci; Alessandro Gasbarrini; Elena Tabacchi; Carlo Piovani; Lisa Argnani; Riccardo Ghermandi; Elena Sabattini; Rita Golfieri; Stefano Fanti; Pier Luigi Zinzani Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-15 Impact factor: 9.236
Authors: Inés C Oría; Juan E Pizzala; Augusto M Villaverde; Dalila C Urgiles; Fernando G Wright; Federico Jauk; Dana Kohan; Mariano M Marcolongo Journal: Radiol Case Rep Date: 2021-03-26
Authors: Alexander Chan; Jose Victor Scarpa Carniello; Qi Gao; Allison Sigler; Jeeyeon Baik; Mikhail Roshal; Oscar Lin Journal: Arch Pathol Lab Med Date: 2022-04-01 Impact factor: 5.686